Macular vitelliform lesion in desferrioxamine-related retinopathy.
To report a case of a macular vitelliform lesion associated with desferrioxamine treatment. Ocular, electrophysiological, psychophysical, perimetric, fluorescein angiographic, fundus autofluorescence, and spectral-domain OCT examinations were obtained on a 45-year-old Caucasian woman with thalassemia major treated with blood transfusions and desferrioxamine. The patient was observed to have a vitelliform macular lesion in the right eye with a hypopigmented macular lesion and retinal pigment mottling in the left. At the most recent follow-up visit, best-corrected visual acuity was 20/70 in the right eye and 20/25 in left. Full-field electroretinogram (ERG) testing showed normal cone and rod responses. Mild localized elevations of rod psychophysical thresholds were found. A vitelliform macular lesion can develop in patients treated with desferrioxamine. Some such patients may not show diffuse photoreceptor cell functional loss as determined by electrophysiological testing.
Genead
Mohamed A
MA
Department of Ophthalmology and Visual Sciences (MC 648), University of Illinois at Chicago, Room 3.85, Eye and Ear Infirmary, 1855 W Taylor Street, Chicago, IL 60612-7234, USA.
Fishman
Gerald A
GA
Anastasakis
Anastasios
A
Lindeman
Martin
M
D003676:Deferoxamine / Q000009:adverse effects*; D004596:Electroretinography; D005260:Female; D005451:Fluorescein Angiography; D006801:Humans; D008875:Middle Aged; D012164:Retinal Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000503:physiopathology; D017262:Siderophores / Q000009:adverse effects*; D014792:Visual Acuity; D058609:Visual Field Tests; D014794:Visual Fields / Q000502:physiology; D017086:beta-Thalassemia / Q000188:drug therapy
D017262:Siderophores; D003676:Deferoxamine